Nephrogen, a biotech firm, is developing a gene therapy to reverse polycystic kidney disease (PKD). The primary challenge involves creating a mechanism for direct drug delivery to diseased cells.
The company is combining artificial intelligence and gene therapy to target and treat kidney diseases. Their initial focus is on PKD, a condition affecting approximately 600,000 Americans and currently lacking effective treatments or a cure.
Nephrogen's work offers hope for curative treatments for genetic kidney diseases.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
